Career

Three physician-researchers have been named to leadership positions at ASCO – Dana-Farber Cancer Institute

Photo taken from Dana-Farber Cancer Institute/LinkedIn

Jun 6, 2024, 07:26

Three physician-researchers have been named to leadership positions at ASCO – Dana-Farber Cancer Institute

Dana-Farber Cancer Institute shared a post on LinkedIn:

“Three physician-researchers have been named to leadership positions at the American Society of Clinical Oncology (ASCO).

Toni Choueiri, director of the Lank Centre for Genitourinary Oncology and medical director of international strategic initiatives, and Abby Rosenberg, chief of Paediatric Palliative Care, have been elected to four-year terms on the ASCO Board of Directors.

The Board, which includes cancer physicians and clinical researchers from a range of specialties, leads and sets policies for ASCO, the leading organization for physicians and other professionals caring for people with cancer.

Kimmie Ng, associate chief of Gastrointestinal Oncology, was elected to a three-year term on the ASCO Nominating Committee, which develops slates of candidates for elected ASCO positions. ‘It is an incredible honor to be elected for a seat on the Nominating Committee,’ remarks Ng.

‘ASCO has played a huge role in my academic career and success, and I am looking forward to giving back by helping select future leaders who will continue to promote the important mission and goals of ASCO.’

The terms on the Board and Nominating Committee begin this month.”

Source: Dana-Farber Cancer Institute/LinkedIn

Abby Rosenberg American Society of Clinical Oncology ASCO cancer Dana-Farber Cancer Institute Kimmie Ng Lank Centre for Genitourinary Oncology OncoDaily Oncology Paediatric Palliative Care

Agenus announced new data highlighting BOT/BAL across multiple lines of treatment in Colorectal Cancer

OncoDaily Acquires CancerWorld: A New Era in Oncology Media

FDA approved sotorasib with panitumumab for KRAS G12C-mutated colorectal cancer

Oncologist Near Me - Vivek Subbiah: Pionner of Precision Oncology

Monica Bertagnolli is ending her tenure as NIH director